Propanc Biopharma, Inc.

Overview

Compare with another stock.

• TickerPPCB on Nasdaq²
• IndustryPharmaceutical Preparations²
• HeadquartersMelbourne, Australia²
• Incorporated inDE⁴
• Business address302/6 Butler Street, Camberwell, Victoria, C3 3124⁴
• Filer categoryNon-accelerated filer, Smaller reporting company⁴
• Legal formCorporation²
• LEI549300Q3HY827FNV8Y56²
• StatusActive²
• LEI statusIssued and current²
• Registered addressc/o CORPORATE CREATIONS NETWORK INC., 1521 CONCORD PIKE SUITE 201, 19803 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 4902919²

See how the biggest companies compare on our leaderboards

Whereas purification and yield of chymotrypsinogen is currently the focus of research.⁵ From its latest annual report

Corporate structure

Propanc Biopharma, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Propanc Biopharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Properties, in its own words

Our principal executive office is located at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia, which we lease from Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our Chief Executive Officer, Chief Financial Officer and a director, and his wife are owners and directors. On May 4, 2022, the Company entered into a three-year lease agreement with North Horizon Pty Ltd. for a monthly rent of $3,000 AUD or $2,176 USD (depending on exchange rate) per month plus taxes. On May 4, 2025, the Company entered into a one-year lease agreement with North Horizon Pty Ltd., a related party, for a monthly rent of $3,300 AUD or $2,127 USD (depending on exchange rate) per month plus taxes with an option to renew the lease for an additional two-year term.

Item 2 of the 10-K filed Sep 25, 2026.⁵

Leadership

Who has led Propanc Biopharma, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerJames Andrew Nathanielsz Jul 26, 2012 to Aug 20, 2021¹⁴
• ChairJames Andrew Nathanielsz May 17, 2019 to May 17, 2019¹⁵
• Chief financial officerCarlo M. Campiciano Jun 28, 2019 to Jun 28, 2019¹⁶
• Chief financial officerJames Andrew Nathanielsz Sep 27, 2016 to Aug 20, 2021¹⁷

Former names

• Propanc Health Group CorpJun 23, 2011 to Apr 5, 2017⁴

Timeline

1. Jul 14, 20268-K Executive or director change²¹
2. Feb 26, 20268-K Executive or director change²²
3. Jan 7, 20268-K Listing notice or transfer²³
4. Nov 10, 20258-K Unregistered sale of shares; Bylaws or fiscal year changed²⁴
5. Oct 14, 20258-K Entered a material agreement²⁵
6. Aug 19, 20258-K Entered a material agreement; Executive or director change; Other events²⁶
7. Aug 13, 20258-K Executive or director change²⁷
8. Jul 30, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²⁸
9. Jul 22, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²⁹
10. Jun 27, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares³⁰
11. Jun 18, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares³¹
12. Jun 2, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares³²
13. Jul 26, 2012New chief executive James Andrew Nathanielsz becomes CEO¹⁴
14. Nov 23, 2010Founded Propanc Biopharma, Inc. is founded²

Calendar

Coming up

1. Nov 13, 2026Reports results for the quarter ending Sep/2026³³

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

165 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 1 insider forms, 2 large holders, 7 private raises, 74 other. The latest 20:

1. Oct 8, 2026PRE 14C EDGAR
2. Oct 5, 2026S-1 EDGAR
3. Sep 25, 202610-K EDGAR
4. Aug 21, 2026DEF 14C EDGAR
5. Aug 5, 2026PRE 14C EDGAR
6. Jul 27, 2026EFFECT EDGAR
7. Jul 17, 2026S-1 EDGAR
8. Jul 14, 20268-K EDGAR
9. May 14, 202610-Q EDGAR
10. Apr 20, 2026EFFECT EDGAR
11. Apr 16, 2026CORRESP EDGAR
12. Apr 15, 2026UPLOAD EDGAR
13. Apr 10, 2026S-1 EDGAR
14. Mar 31, 2026DEF 14C EDGAR
15. Mar 20, 2026PRE 14C EDGAR
16. Mar 19, 2026PRE 14A EDGAR
17. Mar 6, 2026424B3 EDGAR
18. Feb 26, 20268-K EDGAR
19. Feb 24, 2026EFFECT EDGAR
20. Feb 20, 2026CORRESP EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Ionic Ventures, LLCSCHEDULE 13G/A, 2 filings Aug 19, 2025 to Nov 14, 2025³⁴

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Oct 20, 2023Raised $40,000 in a private offering of debt³⁵ Form D: 1 investor so far Form D
2. Oct 12, 2023Raised $61,000 in a private offering of debt³⁶ Form D: 1 investor so far Form D
3. Aug 23, 2023Raised $72,500 in a private offering of debt³⁷ Form D: 1 investor so far Form D
4. Aug 16, 2023Raised $55,000 in a private offering of debt³⁸ Form D: 1 investor so far Form D
5. Aug 15, 2023Raised $120,000 in a private offering of debt³⁹ Form D: 1 investor so far Form D
6. Jul 19, 2023Raised $45,000 in a private offering of debt⁴⁰ Form D: 1 investor so far Form D
7. Jun 29, 2023Raised $65,000 in a private offering of debt⁴¹ Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Propanc Biopharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARPropanc Biopharma, Inc.¹
• CIK0001517681
• Employer ID (EIN)33-0662986⁵
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company⁵
• Incorporated inDelaware⁵
• Fiscal year endsJune 30¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address302/6 Butler Street, Camberwell, Victoria, C3 3124¹
• Phone61-03-9882-0780¹
• Shares outstanding6,331,116 shares as of Sep 23, 2026⁵
• Public float$2.7M as of Dec 31, 2025⁵
• AuditorSALBERG & COMPANY, P.A, Boca Raton, Florida PCAOB ID 106⁵
• On EDGAR sinceJun 23, 2011¹
• Filings436 in all: 8-K (129), 10-Q (44), CORRESP (37), 424B3 (25), S-1/A (24), UPLOAD (24), EFFECT (21), S-1 (17)¹
  All 32 form types

  10-K (15), D (15), PRE 14C (15), DEF 14C (13), 4 (9), NT 10-Q (8), POS AM (7), NT 10-K (6), SC 13G (5), 3 (4), RW (3), 424B4 (2), PRER14C (2), 10-Q/A (1), 3/A (1), 8-A12B (1), 8-A12G (1), 8-K/A (1), CERT (1), PRE 14A (1), RW WD (1), SC 13D (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (10-K) Sep 25, 2026
  Quarterly report (10-Q) May 14, 2026
  Latest 8-K (8-K) Jul 14, 2026

Risk factors and legal proceedings

Legal proceedings

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, or proceeding by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or our subsidiary, threatened against or affecting our Company, our Common Stock, our subsidiary or of our companies or our subsidiary’s officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

IRS Liability

As part of its requirement for having a foreign operating subsidiary, the Company’s parent U.S. entity is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $10,000 per year, or $30,000 in total, plus accrued interest, such penalty and interest having been accrued and is included in the accrued expenses and other payable figure in the June 30, 2026 and 2025 consolidated balance sheets. The Company recorded the penalties for all three years during the year ended June 30, 2018. The Company is current on all subsequent filings.

The opening of Item 3, Legal Proceedings.⁵